QZIT® GRANTED MOPH MARKETING APPROVAL
-250 and 500 mg film coated antibiotic tablets -
DOHA, April 19, 2021 – QLife pharma today announced that the Qatar MOPH has granted marketing approval for prescription QZIT® (Azithromycin 250mg/500mg) film coated tablets. QZIT® is a class of antibiotic called macrolides and is indicated for various infections like Upper and Lower Respiratory tract infections, Urinary tract infections and skin infections. QZIT® is the first Azithromycin with 250mg and 500mg strengths approved by MOPH for Qatar market.
“QZIT® is unique among the available antibiotics by having short duration of course and it requires less frequent administration for patients, increasing compliance towards medicine. Various studies reveal that QZIT® is more effective and more compliant than currently used other class of antibiotics in various infectious conditions. We believe QZIT® provides an excellent alternative for physicians and patients who would prefer a better and well tolerated antibiotic. QZIT® is safe in pediatric patients. We believe this important differentiation should give QZIT® a distinct advantage in the marketplace.”
QLife Pharma is a privately-owned, Qatar based generic pharmaceutical company, manufacturing, and marketing pharmaceutical products in the therapeutic areas of gastroenterology, cardiovascular, anti-infective and pain management. QLife pharma is evolving in this sector in GCC and is unique in having a balanced sales presence across all GCC countries.
QZIT® (Azithromycin 250/500mg) film coated tablets are indicated for various infections in adults as well as children with dose adjustments.
For full prescribing information on QLife Pharma products, please visit http://www.qlifepharma.com/
Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include market acceptance for approved products, management of rapid growth, risks of regulatory review and clinical trials, intellectual property risks, and the need to acquire additional products. The reader is referred to the documents that the Company files from time to time with the Securities and Exchange Commission.